This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
(MedPage Today) -- As a physician who is hard of hearing, I was excited to learn about FDA's authorization of Apple's newest AirPods, which will come with the capability to convert into hearing aids. If the AirPods live up to their promise, individuals.
Sudden cardiac death (SCD) remains a major health problem in all continents. It usually affects older patients suffering from coronary artery disease and cardiomyopathies. However, a morphologically normal heart during autopsy has been a frequent finding, ranging from 40% to 78% in victims aged 10 to 49 years old (1-5). This group of patients defines the sudden arrhythmic death syndrome (SADS) where the cause of death is unknown.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.
Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.
Two devices approved by the U.S. Food and Drug Administration (FDA) this year for tricuspid regurgitation (TR) are safe, effective and improve quality of life (QOL) at one year, according to studies published in JACC and simultaneously being presented at TCT 2024.
Diabetes mellitus (DM) is associated with premature atherosclerotic disease, coronary artery disease (CAD) and chronic heart failure (HF), leading to increased morbidity and mortality. Sodium-Glucose Co-transp.
In this interview, Neal Bhatia, MD, and Laura Korb Ferris, MD, PhD, spoke on their Fall Clinical Conference talk titled ‘Beyond the Biopsy: Other Methods To Help Us Manage Skin Cancer.
It’s well known that heart disease is the U.S.’s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. Heart Disease in 2050 – The AHA warned of massive heart disease increases by 2050, spanning CVD (+60%), diabetes (+100%), obesity (+70%), hypertension (+44%), heart failure (+66%), and stroke (+100%).
Circulation, Ahead of Print. BACKGROUND:In patients with out-of-hospital cardiac arrest who present with an initial shockable rhythm, a longer delay to the first shock decreases the probability of survival, often attributed to cerebral damage. The mechanisms of this decreased survival have not yet been elucidated. Estimating the probability of successful defibrillation and other factors in relation to the time to first shock may guide prehospital care systems to implement policies that improve p
Systemic stress, inflammation, and hydroelectrolytic and acid‒base abnormalities observed during diabetic ketoacidosis (DKA) can cause changes in the heart and even induce cardiovascular damage. We aimed to ev.
The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.
Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.
This interview features a discussion with Bhatia and Ferris regarding the necessity of collaboration between dermatologists and oncologists for skin cancer.
The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.
Hyperglycemia upon admission is associated with poor prognosis of many cardiovascular diseases. However, the relationship of stress hyperglycemia ratio (SHR), admission blood glucose (ABG), and hemoglobin A1c.
Calmodulinopathy is a rare genetic disorder caused by mutations in the calmodulin genes, often presenting with malignant ventricular arrhythmias during infancy or early childhood.1,2 Despite aggressive management with standard therapies, the prognosis remains poor. We present a case of a neonate with severe QTc prolongation due to a CALM1 gene variant.
Little has been reported on the predictors of late recurrence (LR) after second radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF).
New science presented at TCT 2024 and simultaneously published across the family of JACC Journals sheds light on topics including photon-counting detector-computed tomography (PCD-CT), new and emerging technologies for treating patients with cardiovascular diseases, fractional flow reserve (FFR) and resting full-cycle ratio for predicting myocardial ischemia, intravascular ultrasound (IVUS)-guided PCI in patients with diabetes and acute coronary syndrome (ACS), left atrial appendage occlusion (L
Esophageal cancer is the sixth leading cause of cancer-related mortality worldwide; with esophageal adenocarcinoma being the more common subtype in the West. For patients with localized or locally advanced esophageal adenocarcinoma, esophagectomy is necessary for pursuing a curative intent approach. One of the standard approaches typically involves neoadjuvant concurrent chemoradiation with carboplatin and paclitaxel followed by esophagectomy, as established by the phase III CROSS trial [1].
Background Echocardiography, cardiac magnetic resonance and cardiac 18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging play key roles in the diagnosis and management of cardiac sarcoidosis (CS), but the relative value of each modality in predicting outcomes has yet to be determined. This study sought to determine the prognostic importance of multimodality imaging data over and above demographic characteristics and left ventricular ejection fraction (LVEF).
A LAmbre disc occluder (LifeTech Scientific, Shenzhen, China), size 24–30 mm (comprising a 24-mm fixed umbrella and a 30-mm sealing disc) was deployed in a wing-shaped left atrial appendage (LAA), with its sealing disc closely attached to the pulmonary ridge (PR; red dashed line) before release. Post-release, as shown in Figure 1A and the Supplemental Video, while the umbrella remained in place within the landing zone, the upper part of the sealing disc (yellow dotted line) shifted away from the
Aims We set out to explore associations between a ‘mitral-specific’ cardiac damage score (m-CDS) and survival outcomes in mitral regurgitation (MR) and compare the performance of the m-CDS and an ‘aortic-specific’ CDS (a-CDS) in patients with MR within the large National Echo Database of Australia. Methods Among 620 831 unique adults investigated with echocardiography, there were 17 658 individuals (3.1%) with moderate or greater functional MR (aged 76±13 years, 51%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content